These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 9333150)

  • 41. Neutralizing antibodies in slowly progressing HIV-1 infection.
    Schønning K; Nielsen C; Iversen J; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):400-7. PubMed ID: 7583435
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.
    Kessler JA; McKenna PM; Emini EA; Chan CP; Patel MD; Gupta SK; Mark GE; Barbas CF; Burton DR; Conley AJ
    AIDS Res Hum Retroviruses; 1997 May; 13(7):575-82. PubMed ID: 9135875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression.
    Ngo-Giang-Huong N; Candotti D; Goubar A; Autran B; Maynart M; Sicard D; Clauvel JP; Agut H; Costagliola D; Rouzioux C;
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1435-46. PubMed ID: 11679156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
    Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
    Mahalanabis M; Jayaraman P; Miura T; Pereyra F; Chester EM; Richardson B; Walker B; Haigwood NL
    J Virol; 2009 Jan; 83(2):662-72. PubMed ID: 18987151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates.
    Juompan LY; Hutchinson K; Montefiori DC; Nidtha S; Villinger F; Novembre FJ
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):573-86. PubMed ID: 18426337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.
    Dreyer K; Kallas EG; Planelles V; Montefiori D; McDermott MP; Hasan MS; Evans TG
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1563-71. PubMed ID: 10580407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.
    Aasa-Chapman MM; Holuigue S; Aubin K; Wong M; Jones NA; Cornforth D; Pellegrino P; Newton P; Williams I; Borrow P; McKnight A
    J Virol; 2005 Mar; 79(5):2823-30. PubMed ID: 15709001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of the antibody response in acute HIV-1 infection.
    Aasa-Chapman MM; Hayman A; Newton P; Cornforth D; Williams I; Borrow P; Balfe P; McKnight A
    AIDS; 2004 Feb; 18(3):371-81. PubMed ID: 15090788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.
    Hogervorst E; Jurriaans S; de Wolf F; van Wijk A; Wiersma A; Valk M; Roos M; van Gemen B; Coutinho R; Miedema F
    J Infect Dis; 1995 Apr; 171(4):811-21. PubMed ID: 7706807
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.
    Pantaleo G; Menzo S; Vaccarezza M; Graziosi C; Cohen OJ; Demarest JF; Montefiori D; Orenstein JM; Fox C; Schrager LK
    N Engl J Med; 1995 Jan; 332(4):209-16. PubMed ID: 7808486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
    Sagar M; Wu X; Lee S; Overbaugh J
    J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    Frost SD; Wrin T; Smith DM; Kosakovsky Pond SL; Liu Y; Paxinos E; Chappey C; Galovich J; Beauchaine J; Petropoulos CJ; Little SJ; Richman DD
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18514-9. PubMed ID: 16339909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.
    Haigwood NL; Montefiori DC; Sutton WF; McClure J; Watson AJ; Voss G; Hirsch VM; Richardson BA; Letvin NL; Hu SL; Johnson PR
    J Virol; 2004 Jun; 78(11):5983-95. PubMed ID: 15140996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.